Artificial Intelligence (AI)-Enhanced Sleep Apnea Oral Device Global Market Report 2025

The artificial intelligence (AI)-enhanced sleep apnea oral device market size has grown rapidly in recent years. It will grow from $1.17 billion in 2024 to $1.33 billion in 2025 at a compound annual growth rate (CAGR) of 13.8%. Growth during the historic period can be attributed to the increasing prevalence of sleep apnea disorders, rising awareness of the complications associated with untreated sleep apnea, growing demand for noninvasive treatments for sleep disorders, higher diagnosis rates through sleep clinics, expansion of dental sleep medicine practices, and the rising number of patients opting for customized oral appliances.

The artificial intelligence (AI)-enhanced sleep apnea oral device market size is expected to see rapid growth in the next few years. It will grow to $2.2 billion in 2029 at a compound annual growth rate (CAGR) of 13.4%. Growth during the forecast period can be attributed to the increasing emphasis on early detection and management of sleep apnea, rising preference for home-based sleep care solutions, growing healthcare spending on sleep-related disorders, increasing collaboration between dental and medical professionals, expansion of insurance coverage for oral appliance therapies, and growing awareness initiatives promoting sleep health. Key trends in the forecast period include technological progress in oral appliance design and fit optimization, advancements in sensor integration for real-time sleep monitoring, innovations in adaptive and self-adjusting oral device mechanisms, developments in data connectivity and remote performance tracking, research and development in biocompatible and lightweight materials, and advancements in patient-specific digital modeling for customized device production.

The increasing healthcare expenditure is expected to drive the growth of the artificial intelligence (AI) enhanced sleep apnea oral device market in the coming years. Healthcare expenditure refers to the total spending on medical services, treatments, and health-related products aimed at maintaining or improving population health. This expenditure is rising due to the growing prevalence of chronic diseases that require long-term management and ongoing medical care, leading to higher overall healthcare costs. Increased healthcare spending supports the adoption of artificial intelligence (AI) enhanced sleep apnea oral devices by enabling greater investment in advanced diagnostic and treatment technologies that enhance patient outcomes and lower long-term healthcare expenses. For example, in April 2025, the Office for National Statistics, a government agency in the United Kingdom, reported that government-funded healthcare accounted for the majority of total health spending in the country, reaching $346 billion (£258 billion) in 2024, a 2.5 percent real-terms increase compared to 2023. Therefore, the rising healthcare expenditure is contributing to the growth of the artificial intelligence (AI) enhanced sleep apnea oral device market.

Leading companies in the artificial intelligence (AI) enhanced sleep apnea oral device market are focusing on developing innovative designs, such as bioengineered 3D anatomical designs, to enhance device precision, personalization, and treatment effectiveness. Bioengineered 3D anatomical design is an advanced approach that uses artificial intelligence and robotic manufacturing to produce customized oral devices tailored to each patient’s dental and airway structure, improving comfort, jaw alignment, and breathing efficiency. For instance, in June 2025, ProSomnus Inc., a medical device company based in the United States, introduced EVO Guided, a precision-engineered, custom oral device for the treatment of obstructive sleep apnea (OSA). The device offers superior comfort through a lingual-less design, enhancing patient compliance and reducing side effects compared to traditional appliances. Its advanced anatomical fit and patented post mechanism effectively expand airway regions, making it a highly effective, FDA-cleared alternative to CPAP therapy.

In September 2024, US ENT Partners, a group purchasing organization based in the United States, partnered with ProSomnus Inc. to improve access to precision oral appliance therapy for patients with obstructive sleep apnea (OSA). This collaboration aims to empower ENT and dental sleep medicine professionals with advanced AI-enhanced oral appliance therapy solutions that improve patient outcomes, facilitate access to effective OSA treatment, and support practice growth through clinical and reimbursement assistance. ProSomnus Inc. is a United States-based medical device company that manufactures artificial intelligence (AI) enhanced sleep apnea oral devices.

Major players in the artificial intelligence (ai)-enhanced sleep apnea oral device market are ResMed Inc., Glidewell Laboratories Inc., National Dentex Corporation, Dandy, DynaFlex Inc., OrthoApnea S.L., SomnoMed Limited, Panthera Dental, Apex Dental Sleep Lab Inc., Dentulu Inc., Dream Systems LLC, Apnea Sciences Corporation, Good Sleep Co., Open Airway Dental Solutions Ltd., ProSomnus Sleep Technologies Inc., Achaemenid Innovations LLC, Airway Labs, Dianyx Innovations, Klearway Inc., and TOMED GmbH.

North America was the largest region in the artificial intelligence (AI)-enhanced sleep apnea oral device market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in artificial intelligence (AI)-enhanced sleep apnea oral device report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The fast surge in U.S. tariffs and the trade tensions that followed in spring 2025 are heavily affecting the medical equipment sector, particularly for imported imaging machine components, surgical-grade stainless steel, and plastic disposables. Hospitals and clinics resist price hikes, pressuring manufacturers’ margins. Regulatory hurdles compound the problem, as tariff-related supplier changes often require re-certification of devices, delaying time-to-market. Companies are mitigating risks by dual-sourcing critical parts, expanding domestic production of commoditized items, and accelerating R&D in cost-efficient materials.

The artificial intelligence (AI)-enhanced sleep apnea oral device market research report is one of a series of new reports that provides artificial intelligence (AI)-enhanced sleep apnea oral device market statistics, including artificial intelligence (AI)-enhanced sleep apnea oral device industry global market size, regional shares, competitors with a artificial intelligence (AI)-enhanced sleep apnea oral device market share, detailed artificial intelligence (AI)-enhanced sleep apnea oral device market segments, market trends and opportunities, and any further data you may need to thrive in the artificial intelligence (AI)-enhanced sleep apnea oral device industry. This artificial intelligence (AI)-enhanced sleep apnea oral device market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

An artificial intelligence (AI) enhanced sleep apnea oral device is an intelligent, custom-fitted appliance developed to maintain an open airway during sleep by gently adjusting the position of the jaw or tongue. It employs artificial intelligence to monitor breathing patterns in real time, adapting based on the user’s sleep data to enhance both comfort and effectiveness.

The primary product categories of artificial intelligence (AI) enhanced sleep apnea oral devices include mandibular advancement devices, tongue-retaining devices, hybrid devices, and others. A mandibular advancement device works by gently moving the lower jaw forward during sleep to widen the upper airway and prevent its collapse. These devices feature advanced technologies such as artificial intelligence (AI) based monitoring, smart sensors, and data analytics and are distributed through both online and offline channels. They are used for applications such as obstructive sleep apnea, central sleep apnea, and complex sleep apnea syndrome, catering to end users including hospitals, sleep clinics, home care environments, and others.

The countries covered in the artificial intelligence (AI)-enhanced sleep apnea oral device market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The artificial intelligence (AI)-enhanced sleep apnea oral device market consists of revenues earned by entities by providing services such as custom fitting, remote monitoring, sleep data analysis, teleconsultation, maintenance and repair, and software updates. The market value includes the value of related goods sold by the service provider or included within the service offering. The artificial intelligence (AI)-enhanced sleep apnea oral device market also includes sales of oral appliances, sensor modules, adaptive control systems, and digital sleep trackers. Values in this market are ‘factory gate’ values; that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.